Appendiceal Mucinous Neoplasm clinical trials at University of California Health

1 research study open to eligible people

Metformin in Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms
open to eligible people ages 18 years and up
This is a pilot, open-label clinical trial determining the feasibility of metformin therapy in subjects with pseudomyxoma peritonei (PMP) secondary to appendiceal mucinous neoplasms (AMNs).
at UC Irvine

Last updated: July 9, 2026